Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA

Background: There is a paucity of data on mortality and causes of death (CoDs) in patients with sporadic inclusion body myositis (sIBM), a rare, progressive, degenerative, inflammatory myopathy that typically affects those aged over 50 years. Objective: Based on patient records and expertise of clinical specialists, this study used questionnaires to evaluate physicians’ views on clinical characteristics of sIBM that may impact on premature mortality and CoDs in these patients. Methods: Thirteen physicians from seven countries completed two questionnaires online between December 20, 2012 and January 15, 2013. Responses to the first questionnaire were collated and presented in the second questionnaire to seek elaboration and identify consensus. Results: All 13 physicians completed both questionnaires, providing responses based on 585 living and 149 deceased patients under their care. Patients were reported to have experienced dysphagia (60.2%) and injurious falls (44.3%) during their disease. Over half of physicians reported that a subset of their patients with sIBM had a shortened lifespan (8/13), and agreed that bulbar dysfunction/dysphagia/oropharyngeal involvement (12/13), early-onset disease (8/13), severe symptoms (8/13), and falls (7/13) impacted lifespan. Factors related to sIBM were reported as CoDs in 40% of deceased patients. Oropharyngeal muscle dysfunction was ranked as the leading feature of sIBM that could contribute to death. The risk of premature mortality was higher than the age-matched comparison population. Conclusions: In the absence of data from traditional sources, this study suggests that features of sIBM may contribute to premature mortality and may be used to inform future studies.

[1]  J. Gran,et al.  High prevalence of inclusion body myositis in Norway; a population‐based clinical epidemiology study , 2015, European journal of neurology.

[2]  F. Mastaglia,et al.  Sleep disordered breathing and subclinical impairment of respiratory function are common in sporadic inclusion body myositis , 2014, Neuromuscular Disorders.

[3]  L. Servais,et al.  Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: Implications for therapeutic trials , 2014, Neuromuscular Disorders.

[4]  L. Crofford,et al.  New Insights into the Benefits of Exercise for Muscle Health in Patients with Idiopathic Inflammatory Myositis , 2014, Current Rheumatology Reports.

[5]  P. Carstens,et al.  Diagnosis, pathogenesis and treatment of myositis: recent advances , 2014 .

[6]  E. Scarano,et al.  Sleep disordered breathing in a cohort of patients with sporadic inclusion body myositis , 2013, Clinical Neurophysiology.

[7]  B. Weinshenker,et al.  Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis , 2013, Multiple sclerosis.

[8]  I. Nonaka,et al.  Increase in number of sporadic inclusion body myositis (sIBM) in Japan , 2012, Journal of Neurology.

[9]  David Hilton-Jones,et al.  Long-term observational study of sporadic inclusion body myositis. , 2011, Brain : a journal of neurology.

[10]  J. Verschuuren,et al.  A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. , 2011, Brain : a journal of neurology.

[11]  Y. Parman,et al.  Sporadic-inclusion body myositis (s-IBM) is not so prevalent in Istanbul/Turkey: a muscle biopsy based survey , 2011, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[12]  R. Barohn,et al.  Inclusion body myositis: old and new concepts , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  F L Mastaglia,et al.  Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC. , 2009, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[14]  J. Holton,et al.  Sporadic inclusion body myositis: an unsolved mystery. , 2009, Acta reumatologica portuguesa.

[15]  Allan D. Kirk,et al.  Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis , 2009, Brain : a journal of neurology.

[16]  Timothy Day,et al.  Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis , 2008, Journal of Clinical Neuroscience.

[17]  J. Kasperbauer,et al.  Dysphagia in Inclusion Body Myositis: Clinical Features, Management, and Clinical Outcome , 2008, American journal of physical medicine & rehabilitation.

[18]  I. Lundberg,et al.  Mortality in idiopathic inflammatory myopathies. , 2008, Clinical and experimental rheumatology.

[19]  F L Mastaglia,et al.  Inflammatory muscle diseases. , 2008, Neurology India.

[20]  F L Mastaglia,et al.  Sporadic inclusion body myositis: Phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[21]  A. Shatunov,et al.  T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis , 2007, Neurology.

[22]  Marinos C. Dalakas,et al.  Upregulation of thrombospondin-1(TSP-1) and its binding partners, CD36 and CD47, in sporadic inclusion body myositis , 2007, Journal of Neuroimmunology.

[23]  Marinos C. Dalakas,et al.  β‐Amyloid is a substrate of autophagy in sporadic inclusion body myositis , 2007 .

[24]  K J Felice,et al.  Inclusion Body Myositis in Connecticut: Observations in 35 Patients During an 8-Year Period , 2001, Medicine.

[25]  R. Griggs,et al.  A prospective natural history study of inclusion body myositis , 2001, Neurology.

[26]  F. Breedveld,et al.  Epidemiology of inclusion body myositis in the Netherlands: A nationwide study , 2000, Neurology.

[27]  F L Mastaglia,et al.  Prevalence of sporadic inclusion body myositis in Western Australia , 2000, Muscle & nerve.

[28]  A. Oldfors,et al.  Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases , 1994, Acta Neurologica Scandinavica.

[29]  W J Litchy,et al.  Inclusion body myositis. Observations in 40 patients. , 1989, Brain : a journal of neurology.

[30]  N. Dalkey,et al.  An Experimental Application of the Delphi Method to the Use of Experts , 1963 .

[31]  C. Mazia A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities , 2012 .

[32]  J. Lünemann,et al.  Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. , 2007, Annals of neurology.

[33]  S. Munshi,et al.  Inclusion body myositis: an underdiagnosed myopathy of older people. , 2006, Age and ageing.

[34]  Baziel G M van Engelen,et al.  Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. , 2005, Journal of neurology.

[35]  Richard J. Barohn,et al.  Inclusion body myositis , 2000, Current treatment options in neurology.

[36]  D. Buchholz,et al.  Dysphagia in patients with inclusion body myositis. , 1999, Dysphagia.